Skip to content
CRLCharles River Laboratories

CRL Earnings

Charles River Laboratories next reports earnings on November 4, 2026. Track record: 4/4 beats.

Next Earnings In

66Days
:
13Hours
:
32Min
:
10Sec

Wednesday, November 4, 2026

Current Price

$291.50

EPS Estimate

Earnings Per Share

$2.95

+21.5% YoY

Trailing EPS

Last 12 months earnings

-$4.72

Beat Rate

4/4

100%

Forward P/E

Price-to-Earnings ratio

23.0

Margin: -6.0%

Analyst Rating

Buy

14 analysts

Analyst Sentiment

Buy14 analysts
Target: $281.00-3.6%Full analysis →

Trading above average target while rated "Buy." Price may have rallied faster than analysts updated targets.

Earnings History

4/4 Beats
QuarterEPS Est.EPS ActualSurpriseResult
2026-06-30$2.74$3.02+10.3%Beat
2026-03-31$1.95$2.06+5.4%Beat
2025-12-31$2.35$2.39+1.9%Beat
2025-09-30$2.34$2.43+3.9%Beat

Growth Estimates

PeriodEPS Est.Growth
Current Qtr(0q)$2.95+21.5%
Next Qtr(+1q)$3.31+38.7%
Current Year(0y)$11.32+10.1%
Next Year(+1y)$12.69+12.1%

Next Quarter Estimates

EPS Estimate

Earnings Per Share

$2.95

Revenue Estimate

$959M

Annual EPS Est.

$11.32

+10.1% YoY

CRL Earnings FAQ

When is CRL's next earnings date?

Charles River Laboratories (CRL) is expected to report earnings on November 4, 2026. The consensus EPS estimate is $2.95.

Does CRL usually beat earnings estimates?

Charles River Laboratories has beaten Wall Street EPS estimates in 4 of the last 4 quarters (100% beat rate).

What is CRL's trailing EPS?

Charles River Laboratories's trailing twelve-month EPS is -$4.72. This is calculated from the last four quarters of reported earnings.

What do analysts think about CRL?

14 Wall Street analysts cover Charles River Laboratories. The consensus rating is "Buy" with an average price target of $281.00, implying 3.6% downside from the current price.